X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
0
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
Amphastar intends to use the proceeds for the payment of milestone payments in connection with the acquisition of Baqsimi (glucagon) nasal powder, used to treat very low blood sugar (severe hypoglycemia) in people with diabetes ages 4 years and above.
Lead Product(s): Glucagon
Therapeutic Area: Endocrinology Product Name: Baqsimi
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $300.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement September 11, 2023
Details:
Through the divestment, Amphastar will continue Lilly's mission to help more people benefit from Baqsimi (glucagon), the first and only nasally administered glucagon for the treatment of severe hypoglycemia in people with diabetes.
Lead Product(s): Glucagon
Therapeutic Area: Endocrinology Product Name: Baqsimi
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Amphastar Pharmaceuticals
Deal Size: $1,075.0 million Upfront Cash: $625.0 million
Deal Type: Divestment June 30, 2023
Details:
Through the divestment, Amphastar will continue Lilly's mission to help more people benefit from Baqsimi (glucagon), the first and only nasally administered glucagon for the treatment of severe hypoglycemia in people with diabetes.
Lead Product(s): Glucagon
Therapeutic Area: Endocrinology Product Name: Baqsimi
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Amphastar Pharmaceuticals
Deal Size: $1,075.0 million Upfront Cash: $625.0 million
Deal Type: Divestment April 24, 2023
Details:
Gvoke (glucagon) increases blood glucose concentration by activating hepatic glucagon receptors, thereby stimulating glycogen breakdown and release of glucose from the liver.
Lead Product(s): Glucagon
Therapeutic Area: Endocrinology Product Name: Gvoke
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 18, 2023
Details:
Ogluo® is a ready-to-use, ambiently stored, preparation of glucagon that has been specifically designed for patients living with diabetes with severe hypoglycaemia.
Lead Product(s): Glucagon
Therapeutic Area: Endocrinology Product Name: Ogluo
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Arecor
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 12, 2022
Details:
This two-year grant will allow AmideBio to select a long-acting soluble stable glucagon candidate and do the necessary work to support the filing of an Investigational New Drug (IND) application with the FDA at the end of the grant period.
Lead Product(s): Glucagon
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Peptide
Partner/Sponsor/Collaborator: NIDDK
Deal Size: $2.7 million Upfront Cash: Undisclosed
Deal Type: Funding October 04, 2022
Details:
Under the terms of the proposed acquisition, Arecor Therapeutics has agreed to acquire Tetris Pharma and will continue to commercialize Ogluo in the UK and EEA. Gvoke® (US) /Ogluo® (EU), the first prescription, ready-to-use, pre-mixed, pre-measured glucagon injection.
Lead Product(s): Glucagon
Therapeutic Area: Endocrinology Product Name: Ogluo
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Arecor
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 01, 2022
Details:
Under the terms of the applicable agreements, Xeris will be responsible for Gvoke® PFS and Gvoke HypoPen® (glucagon injection) supply and Tetris will be responsible for the commercialization of Ogluo in the Territory.
Lead Product(s): Glucagon
Therapeutic Area: Endocrinology Product Name: Ogluo
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Tetris Pharma
Deal Size: $71.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 19, 2021
Details:
The United Kingdom’s Medicines and Healthcare Regulatory Agency (MHRA) has approved Ogluo® (glucagon) injection for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.
Lead Product(s): Glucagon
Therapeutic Area: Endocrinology Product Name: Ogluo
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 29, 2021
Details:
European Commission (EC) has approved Ogluo™ (glucagon) injection for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.
Lead Product(s): Glucagon
Therapeutic Area: Endocrinology Product Name: Ogluo
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2021
Details:
Megapharm will be responsible for registration and marketing of Gvoke in Israel and the Palestinian Authority, and named patient services supply. Xeris will manufacture, supply, and will take care of the quality assurance and control, regulatory support, and maintenance of IP.
Lead Product(s): Glucagon
Therapeutic Area: Endocrinology Product Name: Gvoke
Highest Development Status: ApprovedProduct Type: Peptide
Partner/Sponsor/Collaborator: Megapharm
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 22, 2020
Details:
The positive Opinion is based on the results from a Phase 3, multi-center, randomized controlled, non-inferiority study to evaluate the liquid stable glucagon auto-injector as a treatment for severe hypoglycemic events compared with Novo Nordisk’s GlucaGen® HypoKit®.
Lead Product(s): Glucagon
Therapeutic Area: Endocrinology Product Name: Ogluo
Highest Development Status: Phase IIIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2020
Details:
Xeris Pharmaceuticals announced positive topline results of a Phase 2 study of its developmental Gvoke RTU Micro™ for the prevention of hypoglycemia during and after moderate-to-high intensity aerobic exercise in adults with Type 1 diabetes mellitus who use insulin pumps.
Lead Product(s): Glucagon
Therapeutic Area: Endocrinology Product Name: Gvoke RTU Micro
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2020
Details:
Rebound hypoglycemia observed in the placebo arm with oral glucose tablet use; No rebound hypoglycemia observed in the RTU glucagon treatment arm.
Lead Product(s): Glucagon
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 22, 2020
Details:
Results show a mini dose (150 µg) of RTU glucagon prevents Exercise-Induced Hypoglycemia (EIH) during prolonged, moderate-to-high intensity aerobic exercise in a clinical research setting.
Lead Product(s): Glucagon
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 06, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
